Effects of Firocoxib, Flunixin Meglumine, and Phenylbutazone on Platelet Function and Thromboxane Synthesis in Healthy Horses.
Authors: Burkett Brenna N, Thomason John M, Hurdle Holly M, Wills Robert W, Fontenot Robin L
Journal: Veterinary surgery : VS
Summary
# Editorial Summary: NSAIDs and Platelet Function in Horses Concerns about bleeding complications have long surrounded perioperative NSAID use in horses, yet evidence directly comparing how different anti-inflammatories affect clotting mechanisms remains sparse. Burkett and colleagues conducted a randomised crossover trial in nine healthy horses, administering firocoxib, flunixin meglumine, or phenylbutazone for five days whilst measuring platelet aggregation and thromboxane B₂ synthesis at baseline, one hour post-administration, and day five. Both flunixin meglumine and phenylbutazone significantly suppressed thromboxane synthesis—a prostanoid essential for platelet activation—at both time points, whereas firocoxib demonstrated no effect on this pathway; despite these biochemical differences, none of the three NSAIDs impaired platelet aggregation or function as measured by turbidimetric aggregometry or platelet function analysis. The practical takeaway is reassuring for routine perioperative use: conventional dosing of these NSAIDs should not compromise the platelet's ability to aggregate and form clots in healthy horses, though the clinical significance of thromboxane suppression remains unclear and warrants further investigation in animals with underlying haemostatic compromise or during more invasive procedures.
Read the full abstract on PubMed
Practical Takeaways
- •All three NSAIDs tested appear safe for perioperative use from a platelet function standpoint, with no measurable impairment of platelet aggregation regardless of duration of use
- •While flunixin and phenylbutazone do suppress thromboxane synthesis, this biochemical change does not translate to detectable platelet dysfunction in this study, though long-term clinical implications remain unclear
- •Firocoxib may offer a theoretical advantage if thromboxane suppression is a concern, though the practical significance of this difference is not established
Key Findings
- •Firocoxib, flunixin meglumine, and phenylbutazone produced no significant effects on platelet aggregation or platelet function at 1 hour or 5 days of administration
- •Flunixin meglumine and phenylbutazone significantly decreased thromboxane B2 synthesis at both 1 hour and 5 days post-administration
- •Firocoxib did not significantly affect thromboxane B2 synthesis at any timepoint tested
- •These findings suggest preoperative NSAID administration is unlikely to cause clinically significant platelet dysfunction in horses